SCHEMBL25207474

SCHEMBL25207474

CC(C)(C)OC(=O)N1CCC(c2ccc(N)c(C3CCCCC3)c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 1/20 0.52
▸ NAMPT P43490 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ EPHX1 P07099 1/20 0.45
▸ HPGD P15428 1/20 0.44
▸ DDB1 Q16531 1/20 0.44
▸ CRBN Q96SW2 1/20 0.44
▸ GPR119 Q8TDV5 5/20 0.44
▸ HRH3 Q9Y5N1 2/20 0.44
▸ ALOX5AP P20292 1/20 0.42
▸ FEN1 P39748 1/20 0.42
▸ PTPN2 P17706 1/20 0.42
▸ PTPN1 P18031 1/20 0.42
▸ PTPN6 P29350 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25539754 0.99 PDE4B (0.53) PDE4BNAMPTKDM4EMAPTTHRB
SCHEMBL25228900 0.94 NAMPT (0.51) PDE4BNAMPTKDM4EMAPTTHRB
SCHEMBL15157112 0.86 NAMPT (0.54) PDE4BNAMPTKDM4EMAPTTHRB
SCHEMBL30778326 0.86 NAMPT (0.54) PDE4BNAMPTKDM4EMAPTTHRB
SCHEMBL5805967 0.85 NAMPT (0.51) PDE4BNAMPTKDM4EMAPTTHRB
SCHEMBL24793972 0.83 NAMPT (0.52) PDE4BNAMPTKDM4EMAPTTHRB
SCHEMBL12479918 0.83 NAMPT (0.52) PDE4BNAMPTKDM4EMAPTTHRB
SCHEMBL25227116 0.83 PDE4B (0.51) PDE4BNAMPTKDM4EMAPTTHRB
SCHEMBL15862956 0.82 NAMPT (0.51) PDE4BNAMPTKDM4EMAPTTHRB
SCHEMBL29976347 0.82 KDM4E (0.53) PDE4BNAMPTKDM4EMAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240308994-A1 ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) 2024-09-19 — — US disclosed
WO-2023096304-A1 ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF 한양대학교 에리카산학협력단 2023-06-01 — — WO disclosed
WO-2023096304-A1 ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF 한양대학교 에리카산학협력단 2023-06-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240308994-A1 ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF CSF1R, CSF3R, IL15RA PDE4B 324/4885NAMPT 2030/4885KDM4E 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback